Brain Heterogeneity in Schizophrenia and Its Association With Polygenic Risk.


Journal

JAMA psychiatry
ISSN: 2168-6238
Titre abrégé: JAMA Psychiatry
Pays: United States
ID NLM: 101589550

Informations de publication

Date de publication:
01 07 2019
Historique:
pubmed: 11 4 2019
medline: 17 6 2020
entrez: 11 4 2019
Statut: ppublish

Résumé

Between-individual variability in brain structure is determined by gene-environment interactions, possibly reflecting differential sensitivity to environmental and genetic perturbations. Magnetic resonance imaging (MRI) studies have revealed thinner cortices and smaller subcortical volumes in patients with schizophrenia. However, group-level comparisons may mask considerable within-group heterogeneity, which has largely remained unnoticed in the literature. To compare brain structural variability between individuals with schizophrenia and healthy controls and to test whether respective variability reflects the polygenic risk score (PRS) for schizophrenia in an independent sample of healthy controls. This case-control and polygenic risk analysis compared MRI-derived cortical thickness and subcortical volumes between healthy controls and patients with schizophrenia across 16 cohorts and tested for associations between PRS and MRI features in a control cohort from the UK Biobank. Data were collected from October 27, 2004, through April 12, 2018, and analyzed from December 3, 2017, through August 1, 2018. Mean and dispersion parameters were estimated using double generalized linear models. Vertex-wise analysis was used to assess cortical thickness, and regions-of-interest analyses were used to assess total cortical volume, total surface area, and white matter, subcortical, and hippocampal subfield volumes. Follow-up analyses included within-sample analysis, test of robustness of the PRS threshold, population covariates, outlier removal, and control for image quality. A comparison of 1151 patients with schizophrenia (mean [SD] age, 33.8 [10.6] years; 68.6% male [n = 790] and 31.4% female [n = 361]) with 2010 healthy controls (mean [SD] age, 32.6 [10.4] years; 56.0% male [n = 1126] and 44.0% female [n = 884]) revealed higher heterogeneity in schizophrenia for cortical thickness and area (t = 3.34), cortical (t = 3.24) and ventricle (t range, 3.15-5.78) volumes, and hippocampal subfields (t range, 2.32-3.55). In the UK Biobank sample of 12 490 participants (mean [SD] age, 55.9 [7.5] years; 48.2% male [n = 6025] and 51.8% female [n = 6465]), higher PRS was associated with thinner frontal and temporal cortices and smaller left CA2/3 (t = -3.00) but was not significantly associated with dispersion. This study suggests that schizophrenia is associated with substantial brain structural heterogeneity beyond the mean differences. These findings may reflect higher sensitivity to environmental and genetic perturbations in patients, supporting the heterogeneous nature of schizophrenia. A higher PRS was associated with thinner frontotemporal cortices and smaller hippocampal subfield volume, but not heterogeneity. This finding suggests that brain variability in schizophrenia results from interactions between environmental and genetic factors that are not captured by the PRS. Factors contributing to heterogeneity in frontotemporal cortices and hippocampus are key to furthering our understanding of how genetic and environmental factors shape brain biology in schizophrenia.

Identifiants

pubmed: 30969333
pii: 2730004
doi: 10.1001/jamapsychiatry.2019.0257
pmc: PMC6583664
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

739-748

Commentaires et corrections

Type : CommentIn
Type : ErratumIn
Type : CommentIn
Type : CommentIn

Références

Schizophr Bull. 2015 Nov;41(6):1224-6
pubmed: 26333841
Mol Psychiatry. 2020 Nov;25(11):3053-3065
pubmed: 30279459
Bioinformatics. 2015 May 1;31(9):1466-8
pubmed: 25550326
Mol Psychiatry. 2016 Apr;21(4):547-53
pubmed: 26033243
Mol Psychiatry. 2018 Jun;23(6):1512-1520
pubmed: 28507318
Neuroimage. 1999 Feb;9(2):179-94
pubmed: 9931268
Schizophr Bull. 2016 Jan;42(1):152-60
pubmed: 26106217
JAMA Psychiatry. 2015 Jul;72(7):635-41
pubmed: 25830477
Curr Top Behav Neurosci. 2018;40:325-352
pubmed: 29696604
PLoS One. 2018 Apr 4;13(4):e0194541
pubmed: 29617452
Lancet. 2016 Jul 2;388(10039):86-97
pubmed: 26777917
Nat Neurosci. 2017 Apr;20(4):513-515
pubmed: 28218917
Schizophr Bull. 2015 Jan;41(1):74-84
pubmed: 25261565
Nature. 2010 Nov 11;468(7321):187-93
pubmed: 21068826
Acta Psychiatr Scand. 2014 Oct;130(4):311-7
pubmed: 24961959
Neuroimage. 2016 Nov 1;141:502-516
pubmed: 27288322
Neuroimage. 2014 May 15;92:381-97
pubmed: 24530839
Neuroimage. 2015 Jul 15;115:117-37
pubmed: 25936807
Schizophr Bull. 2015 May;41(3):736-43
pubmed: 25392519
JAMA Psychiatry. 2018 Mar 1;75(3):287-295
pubmed: 29365026
Mol Psychiatry. 2021 Aug;26(8):3876-3883
pubmed: 32047264
JAMA Psychiatry. 2016 Mar;73(3):221-8
pubmed: 26818099
Nature. 2014 Jul 24;511(7510):421-7
pubmed: 25056061
Schizophr Bull. 2018 Aug 20;44(5):1060-1069
pubmed: 29529270
Schizophr Bull. 2017 Jul 1;43(4):900-906
pubmed: 28008071
Arch Gen Psychiatry. 2003 Dec;60(12):1187-92
pubmed: 14662550
Schizophr Res. 2017 Jun;184:128-136
pubmed: 27989645
Am J Psychiatry. 2016 Apr 1;173(4):373-84
pubmed: 26651391
Schizophr Res. 2018 Jul;197:2-8
pubmed: 29129507
Neuroimage. 2008 Feb 15;39(4):1600-12
pubmed: 18054834
Brain. 2018 Apr 1;141(4):1218-1228
pubmed: 29415119
Neuroimage. 2015 Feb 15;107:107-115
pubmed: 25498430
Neuroimage Clin. 2016 Jun 16;12:93-99
pubmed: 27408794
Neuroimage Clin. 2017 Jun 09;15:719-731
pubmed: 28702349
Neuroimage. 2018 Apr 1;169:407-418
pubmed: 29278774
Neuroimage. 2004;23 Suppl 1:S250-63
pubmed: 15501095
Nature. 2009 Aug 6;460(7256):748-52
pubmed: 19571811
JAMA Psychiatry. 2018 Nov 1;75(11):1146-1155
pubmed: 30304337
Neuropsychol Rev. 2001 Mar;11(1):45-67
pubmed: 11392562
Schizophr Res. 2019 Dec;214:43-50
pubmed: 29274735
JAMA Psychiatry. 2017 Nov 1;74(11):1104-1111
pubmed: 28973084
Neuroimage. 2010 Aug 1;52(1):158-71
pubmed: 20362677
Schizophr Bull. 2018 Jun 6;44(4):854-864
pubmed: 29136250
Mol Psychiatry. 2018 Aug;23(8):1764-1772
pubmed: 29311665
Schizophr Bull. 2014 Nov;40(6):1263-71
pubmed: 24327754
Psychol Med. 2017 Jul;47(10):1848-1864
pubmed: 28241891
Hum Brain Mapp. 2002 Jan;15(1):1-25
pubmed: 11747097
JAMA Psychiatry. 2016 Dec 01;73(12):1251-1259
pubmed: 27829096
Psychol Med. 2011 Jun;41(6):1127-31
pubmed: 20810003
Neuron. 2002 Jan 31;33(3):341-55
pubmed: 11832223
Schizophr Bull. 2017 May 1;43(3):673-680
pubmed: 27169464
Biol Psychiatry. 2018 Nov 1;84(9):644-654
pubmed: 29960671
Front Neurosci. 2016 Mar 07;10:85
pubmed: 27013947
Neurosci Biobehav Rev. 2015 Oct;57:328-49
pubmed: 26254595
Neuroimage. 1999 Feb;9(2):195-207
pubmed: 9931269
Neuroimage. 2012 Aug 15;62(2):774-81
pubmed: 22248573
Ann Gen Psychiatry. 2009 May 15;8:12
pubmed: 19445674
Schizophr Res. 1997 Dec 19;28(2-3):177-85
pubmed: 9468352
PLoS One. 2010 Jan 08;5(1):e8635
pubmed: 20072615

Auteurs

Dag Alnæs (D)

Norwegian Centre for Mental Disorders Research, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Norway.

Tobias Kaufmann (T)

Norwegian Centre for Mental Disorders Research, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Norway.

Dennis van der Meer (D)

Norwegian Centre for Mental Disorders Research, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Norway.

Aldo Córdova-Palomera (A)

Norwegian Centre for Mental Disorders Research, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Norway.

Jaroslav Rokicki (J)

Norwegian Centre for Mental Disorders Research, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Norway.

Torgeir Moberget (T)

Norwegian Centre for Mental Disorders Research, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Norway.

Francesco Bettella (F)

Norwegian Centre for Mental Disorders Research, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Norway.

Ingrid Agartz (I)

Norwegian Centre for Mental Disorders Research, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Norway.
Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.

Deanna M Barch (DM)

Department of Psychological and Brain Sciences, Washington University in Saint Louis, St Louis, Missouri.

Alessandro Bertolino (A)

Psychiatric Neuroscience Group, Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari Aldo Moro, Bari, Italy.

Christine L Brandt (CL)

Norwegian Centre for Mental Disorders Research, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Norway.

Simon Cervenka (S)

Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.

Srdjan Djurovic (S)

Norwegian Centre for Mental Disorders Research, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Norway.
Department of Medical Genetics, Oslo University Hospital, Oslo, Norway.

Nhat Trung Doan (NT)

Norwegian Centre for Mental Disorders Research, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Norway.

Sarah Eisenacher (S)

Central Institute of Mental Health, University of Heidelberg, Mannheim, Germany.

Helena Fatouros-Bergman (H)

Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.

Lena Flyckt (L)

Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.

Annabella Di Giorgio (A)

Psychiatric Neuroscience Group, Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari Aldo Moro, Bari, Italy.
Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.

Beathe Haatveit (B)

Norwegian Centre for Mental Disorders Research, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Norway.

Erik G Jönsson (EG)

Norwegian Centre for Mental Disorders Research, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Norway.
Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.

Peter Kirsch (P)

Central Institute of Mental Health, University of Heidelberg, Mannheim, Germany.
Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.

Martina J Lund (MJ)

Norwegian Centre for Mental Disorders Research, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Norway.

Andreas Meyer-Lindenberg (A)

Central Institute of Mental Health, University of Heidelberg, Mannheim, Germany.
Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.

Giulio Pergola (G)

Psychiatric Neuroscience Group, Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari Aldo Moro, Bari, Italy.

Emanuel Schwarz (E)

Central Institute of Mental Health, University of Heidelberg, Mannheim, Germany.

Olav B Smeland (OB)

Norwegian Centre for Mental Disorders Research, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Norway.

Tiziana Quarto (T)

Psychiatric Neuroscience Group, Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari Aldo Moro, Bari, Italy.

Mathias Zink (M)

Central Institute of Mental Health, University of Heidelberg, Mannheim, Germany.

Ole A Andreassen (OA)

Norwegian Centre for Mental Disorders Research, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Norway.

Lars T Westlye (LT)

Norwegian Centre for Mental Disorders Research, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Norway.
Department of Psychology, University of Oslo, Oslo, Norway.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH